Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT act mut||skin melanoma||sensitive||Imatinib||Guideline||Actionable||Gleevec (imatinib) is included in guidelines as second-line therapy for metastatic or unresectable cutaneous melanoma patients with KIT activating mutations (NCCN.org).||detail...|
|KIT act mut||gastrointestinal stromal tumor||sensitive||Cabozantinib||Preclinical||Actionable||In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719).||25836719|
|KIT act mut||Advanced Solid Tumor||sensitive||PLX9486||Preclinical||Actionable||In a preclinical study, PLX9486 inhibited KIT mutations, including exon 17 mutations, and demonstrated in vivo and in vitro activity against tumors harboring KIT exon 17 mutations (Cancer Res February 1, 2016 76; IA32).||detail...|
|KIT act mut||gastrointestinal stromal tumor||sensitive||Pexidartinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793).||24583793|
|KIT act mut||gastrointestinal stromal tumor||not applicable||N/A||Guideline||Diagnostic||KIT activating mutations aid the diagnosis of gastrointestinal stromal tumor (NCCN.org).||detail...|
|KIT mutant||gastrointestinal stromal tumor||not applicable||N/A||Clinical Study||Diagnostic||KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).||25193432 26276366 25729899|
|KIT mutant||gastrointestinal stromal tumor||sensitive||Imatinib + Infigratinib||Preclinical - Pdx||Actionable||In a preclinical study, Truseltiq (infigratinib) and Gleevec (imatinib) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).||25673643|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).||detail...|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) was well tolerated, resulted in an objective response in 11.3% (16/142, 16 partial responses) and stable disease in 61.3% (87/142) of patients with advanced gastrointestinal stromal tumor harboring KIT (exon 11, n=103; exon 9, n=26; other, n=6) or PDGFRA mutations (n=7), with a median progression-free survival of 5.6 months (PMID: 32804590; NCT02571036).||32804590|
|KIT mutant||melanoma||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) treatment demonstrated manageable safety and preliminary efficacy in patients with KIT-mutated melanoma, and led to an objective response rate of 23% (6/26, 1 complete and 5 partial responses), a median progression-free survival of 7.3 months, and a median duration of response of 7.4 months (Annals of Oncology 32 (2021): S896-S897; NCT02571036).||detail...|
|KIT mutant||melanoma||sensitive||Nilotinib||Phase II||Actionable||In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).||28327988|
|KIT mutant||melanoma||sensitive||Nilotinib||Phase II||Actionable||In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).||28843487|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Avapritinib||Phase I||Actionable||In a Phase I (NAVIGATOR) trial, Ayvakit (avapritinib) treatment resulted in an objective response rate of 13% (7/52, 7 partial responses) and a disease control rate of 63% (33/52) in patients with KIT-mutant gastrointestinal stromal tumor (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|